English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The purpose of this study was to investigate the pharmacokinetic behaviour of mirogabalin in rats and monkeys.Pharmacokinetic parameters of mirogabalin after its oral and intravenous administration were determined. Distribution study, mass balance study, and metabolite identification were also conducted after the oral administration of [ 14 C]mirogabalin.Plasma exposure ( Cmax  and AUC inf ) increased dose-proportionally after the oral administration of mirogabalin at 1, 3, and 10 mg/kg to rats and monkeys. Mean total body clearance (CL tot ) after intravenous administration at 3 mg/kg was 13.5 mL/min/kg in rats and 9.02 mL/min/kg in monkeys, and absolute bioavailability at 3 mg/kg was 97.6% in rats and 85.2% in monkeys. There was a greater recovery of radioactivity in urine than that in faeces after the oral administration of [ 14 C]mirogabalin. The main radioactive component in the plasma, urine, and faeces was mirogabalin. A204-4455 (lactam form), an oxidised metabolite of mirogabalin, mirogabalin  N -glucuronide and  O -glucuronide of oxidised A204-4455 were detected as minor components in monkeys and rats.Mirogabalin administered orally was almost completely eliminated  via  urinary excretion. A small part of the orally administered dose of mirogabalin was metabolised  via  glucuronidation at the amine and carboxylic acid moiety and oxidation as the primary metabolic pathway. The purpose of this study was to investigate the pharmacokinetic behaviour of mirogabalin in rats and monkeys. Pharmacokinetic parameters of mirogabalin after its oral and intravenous administration were determined. Distribution study, mass balance study, and metabolite identification were also conducted after the oral administration of [ 14 C]mirogabalin. Plasma exposure ( Cmax  and AUC inf ) increased dose-proportionally after the oral administration of mirogabalin at 1, 3, and 10 mg/kg to rats and monkeys. Mean total body clearance (CL tot ) after intravenous administration at 3 mg/kg was 13.5 mL/min/kg in rats and 9.02 mL/min/kg in monkeys, and absolute bioavailability at 3 mg/kg was 97.6% in rats and 85.2% in monkeys. There was a greater recovery of radioactivity in urine than that in faeces after the oral administration of [ 14 C]mirogabalin. The main radioactive component in the plasma, urine, and faeces was mirogabalin. A204-4455 (lactam form), an oxidised metabolite of mirogabalin, mirogabalin  N -glucuronide and  O -glucuronide of oxidised A204-4455 were detected as minor components in monkeys and rats. Mirogabalin administered orally was almost completely eliminated  via  urinary excretion. A small part of the orally administered dose of mirogabalin was metabolised  via  glucuronidation at the amine and carboxylic acid moiety and oxidation as the primary metabolic pathway.

Pharmacokinetics and metabolism of mirogabalin, a novel α 2 δ ligand, in rats and monkeys